Loading clinical trials...

Immune Resolution After Staphylococcus Aureus Bacteremia | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761•University of Chicago

Summary

The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia. We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•At least one blood culture positive for S. aureus
•Patients aged ≥18 years
•At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are:
•* Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F)
•* Heart rate greater than 90 beats per minute
•* Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmHg
•* WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils (band forms)

Exclusion Criteria

•Sequential Organ Failure Assessment (SOFA) score \> 12 on day of positive blood cultures
•Survival expected to be \< 7 days from positive blood cultures

Locations (1)

University of Chicago Hospital

Chicago, Illinois, United States

Key Dates

Start Date

June 1, 2013

Primary Completion Date

June 1, 2026

Completion Date

June 1, 2026

Last Updated

August 14, 2025

Enrollment

102

ACTUAL participants

Conditions

Immune Response To SepsisStaphylococcus Aureus Infection

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

NCT05899140

Skin InfectionStaphylococcal Infections+1 more

View study

RECRUITINGPHASE1/PHASE2

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

NCT06319235

Surgical Site InfectionStaphylococcus Aureus Infection+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Immune Resolution After Staphylococcus Aureus Bacteremia

Inclusion Criteria

Exclusion Criteria

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections

Antistaphylococcal Betalactam and Emergence of Resistance

Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus

Livestock Contact and MRSA in Rural Areas